Jacobs Levy Equity Management
PLRX icon

Jacobs Levy Equity Management’s Pliant Therapeutics PLRX Stock Holding History

Jacobs Levy Equity Management’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$905K Buy
718,543
+161,605
+29% +$204K ﹤0.01% 727
2025
Q4 		$679K Buy
556,938
+189,825
+52% +$285K ﹤0.01% 751
2025
Q3 		$543K Buy
+367,113
New +$560K ﹤0.01% 808
2022
Q1 		– Sell
-14,543
Closed -$196K – 1067
2021
Q4 		$196K Buy
+14,543
New +$231K ﹤0.01% 940

Other funds holding PLRX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Jacobs Levy Equity Management's PLRX Position: Q1 2026 in Review

Jacobs Levy Equity Management increased its Pliant Therapeutics (PLRX) stake by 29% in Q1 2026, buying an estimated $204K and bringing the position to 718,543 shares worth $905K. The position accounts for ﹤0.01% of the portfolio, ranked #727.

Jacobs Levy Equity Management first reported a position in PLRX in Q4 2021 and has held it in 4 quarters since. 91 funds tracked by Wall St. Rank hold PLRX as of Q1 2026.

  • Jacobs Levy Equity Management held 718,543 shares of Pliant Therapeutics worth $905K as of Q1 2026.
  • Jacobs Levy Equity Management bought 161,605 Pliant Therapeutics shares in Q1 2026, an estimated $204K.
  • Pliant Therapeutics made up ﹤0.01% of Jacobs Levy Equity Management's portfolio in Q1 2026, its #727 holding.
  • Jacobs Levy Equity Management first reported a position in Pliant Therapeutics in Q4 2021 and has held it in 4 quarters since.
  • 91 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q1 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2026, filed 15 May 2026.